EP0650370A1 - Methods and compositions for targeting specific tissue - Google Patents

Methods and compositions for targeting specific tissue

Info

Publication number
EP0650370A1
EP0650370A1 EP93914334A EP93914334A EP0650370A1 EP 0650370 A1 EP0650370 A1 EP 0650370A1 EP 93914334 A EP93914334 A EP 93914334A EP 93914334 A EP93914334 A EP 93914334A EP 0650370 A1 EP0650370 A1 EP 0650370A1
Authority
EP
European Patent Office
Prior art keywords
vehicle
cells
population
sub
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93914334A
Other languages
German (de)
French (fr)
Other versions
EP0650370A4 (en
Inventor
Yuet Wai Kan
Noriyuki Kasahara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of EP0650370A1 publication Critical patent/EP0650370A1/en
Publication of EP0650370A4 publication Critical patent/EP0650370A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors

Definitions

  • the invention is directed to methods and compositions for preferentially targeting the delivery of a substance, such as a nucleic acid, to specific tissue.
  • cancers originate from one cell type.
  • chemotherapy is the most widely-used approach to control cancer.
  • Such chemotherapy is not tissue specific in terms of delivery of the chemotherapeutic agent. Rather, the adverse effects imparted upon the rapidly dividing cancer cells are also imposed upon normal cells.
  • the invention includes a vehicle for preferentially targeting the delivery of a substance to a sub-population of mammalian cells.
  • the cell sub-population is characterized by the presence of a sub-population-specific first member of a binding pair on the surface of the cells.
  • the vehicle comprises an envelope comprising a recombinant targeting moiety defining a compartment and a substance contained in the compartment.
  • the recombinant targeting moiety comprises first and second domains.
  • the first domain is capable of forming or associating with the envelope of the vehicle whereas the second domain is capable interacting with the first binding member on the surface of the sub- population of cells.
  • the invention also includes methods for preferentially targeting the delivery of a substance to the above sub- population of mammalian cells comprising contacting a population of mammalian cells containing the sub-population with the above vehicle.
  • FIG. 1 depicts the construction of a hybrid erythropoietin-viral envelope gene.
  • FIG. 2 depicts the Western blot analysis of packaging cell sub-clones including the detection of the erythropoietin sequence.
  • FIG. 3 depicts the flow cytometric analysis of packaging cell lines based upon a detection of cell surface EPO epitopes by polyclonal anti-EPO antibodies.
  • FIG. 4 depicts the survivability of HeLa cells (wild- type or expressing the erythropoietin receptor) which have been exposed to neomycin or the retroviral vector encoding a neomycin resistant gene containing the EPO-env protein followed by a treatment with neomycin.
  • FIG. 5 depicts a similar experiment with NIH3T3 cells.
  • a virus containing a hybrid viral envelope protein containing an amino acid sequence corresponding to a portion of the sequence of erythropoietin is capable of preferentially infecting cells displaying the erythropoietin receptor on their surface.
  • a "vehicle" of the invention is defined as any composition comprising an envelope defining a compartment and a substance contained therein that is capable of preferentially targeting the delivery of the substance to a specific sub-population of mammalian cells.
  • the sub-population of mammalian cells is characterized by the presence of a first member of a binding pair on the surface of the sub-population.
  • the vehicle is further defined by the envelope which comprises a "recombinant targeting moiety" capable of forming or associating with the envelope and which imparts cell specificity to the vehicle.
  • the targeting moiety contains at least two domains .
  • the first domain is capable of forming or associating with the envelope of the vehicle whereas the second domain is capable of interacting with the first member of the binding pair on the surface of the sub- population of mammalian cells.
  • the vehicle comprises a "viral vehicle”.
  • the vehicle comprises a "liposome vehicle”.
  • the viral vehicles of the invention are generally formed from naturally occurring viruses and in particular those viruses capable of infecting eukaryotic cells, such as mammalian cells.
  • viruses contain a genome comprising either RNA or DNA which encode a variety of genes necessary for viral transfection and reproduction. Included within the viral genome are nucleic acid sequences encoding various enzymes, e.g., DNA or RNA polymerases and the like and structural proteins which surround the viral genome referred to as "viral coat proteins".
  • capsid protein makes up that part of the virus particle known as the capsid.
  • some viruses further contain a lipid bilayer surrounding the capsid which often contains viral envelope proteins.
  • the capsid protein or envelope protein is used to form the targeting moiety for the viral vehicle of the invention.
  • the targeting moiety contains a domain which is capable of forming or associating with the envelope of the virus vehicle, all or part of the viral coat protein is used to construct the recombinant target moiety. When only a portion of the coat protein is used, that portion of the coat protein which is necessary and sufficient for envelope formation is used.
  • viral envelope proteins such necessary and essential features include the anchoring region and transmembrane region utilized by the envelope protein to display the envelope protein on an infected cell. When a virus containing an envelope protein is used, it is preferred that the targeting moiety contain such anchor and transmembrane regions .
  • the second domain of the target moiety is capable of interacting with the first member of a binding pair which is on the surface of a sub-population of mammalian cells.
  • a binding pair includes receptor-ligand complexes, antigen-antibody complexes, enzyme-substrate complexes and the like.
  • a sub-population of cells can be defined by the presence of one of the binding pairs on the surface of the cells of the population.
  • those cells containing an erythropoietin receptor define a cellular sub-population that can be targeted by utilizing erythropoietin (ligand) in the targeting moiety of the invention as the second domain capable of interacting with the erythropoietin receptor.
  • the receptor can be used in the targeting moiety and the ligand displayed on the surface of the cells of the sub-population.
  • a sub-population of cells can be defined by the presence of an antigen or antibody on the surface of the cells contained within that population.
  • a surface marker contained on the surface of a sub- population of cells can be used to generate monoclonal antibodies by methods well known to those ' skilled in the art.
  • Monoclonal antibodies (especially those containing anchor and transmembrane regions or engineered through cloning and modification of cDNA to contain such sequences) can be used either as the targeting moiety alone (e.g., in a liposome vehicle) or in combination with a protein capable of associating with a viral surface.
  • the targeting moiety essentially comprises a chimeric antibody containing an anchoring and transmembrane region from a viral envelope protein coupled to at least the variable region of a heavy chain Ig molecule which is also associated with the light chain from the antibody.
  • the vehicle of the invention can target a sub-population of lymphoid cells displaying a membrane bound form of an immunoglobulin.
  • the antigen to the membrane bound antibody is used to form the second domain of the targeting moiety.
  • the recombinant targeting moiety used to form the vehicle of the invention contains all or part of the second member of the binding pair.
  • the interaction between binding pairs is based upon an interaction involving a continuous epitope.
  • the minimal component of the second member of the binding pair that can be used in forming a targeting moiety consists of that epitope.
  • the interaction involves a discontinuous epitope.
  • two or more regions within the primary amino acid sequence of the protein are brought into close physical proximity in the tertiary structure of the protein to form the binding epitope.
  • targeting moiety When only a portion of such a protein is used to form the targeting moiety, that portion of the primary amino acid sequence which encompasses such binding regions are preferably included in the targeting moiety so as to provide the strongest possible interaction with the other member of the binding pair located on the sub-population of mammalian cells.
  • the vehicle of the invention preferentially targets the delivery of substance to a sub-population of mammalian cells.
  • Such preferential targeting is defined by comparing delivery of the substance to the sub-population of mammalian cells containing the first member of a binding pair as compared to a different population of a mammalian cell of the same species which does not display the first member of the binding pair.
  • the increase in delivery as measured by binding of the vehicle to the sub-population or transferral of the substance of the vehicle into the sub- population cells is generally greater than two-fold.
  • an increase in efficiency in infection by the viral vehicle disclosed therein ranged from 10-fold to about 30- to 40-fold as compared to wild-type cells not containing the receptor used in that experiment .
  • the recombinant targeting moiety comprises a carboxy terminal portion of the envelope protein of Moloney murine leukemia virus (MoMLV) .
  • the second domain comprises an amino terminal portion of erythropoietin.
  • a viral vehicle of the invention is formed.
  • the recombinant targeting moiety is associated with the envelope (corresponding to the membrane and MoMLV envelope protein) defining a compartment that contains the remainder of the virus particle.
  • the substance contained within the viral compartment can comprise protein surrounding the viral genome or the genome itself.
  • preformed proteins capable of being packaged with viral capsid proteins can comprise the substance contained in the compartment.
  • the substance of interest contained within such a viral vehicle is a recombinant DNA sequence introduced into the genome of the virus.
  • Viral vehicles are preferred when the substance to be delivered to a sub-population of cells is a nucleic acid.
  • the viral vehicle of the invention is then designed to contain a recombinant targeting moiety capable of forming or associating with the envelope of a selected virus such that the thus modified virus is capable of recognizing and binding the selected surface marker.
  • a recombinant targeting moiety capable of forming or associating with the envelope of a selected virus such that the thus modified virus is capable of recognizing and binding the selected surface marker.
  • the size of the recombinant nucleic acid to be incorporated into the viral genome is determined to facilitate the choice of virus to be used.
  • the genome of the virus must be such that it can either accommodate the selected recombinant nucleic acid or be modified to delete nonessential sequences such that the recombinant nucleic acid can be incorporated into the viral genome and still be packaged to form an intact viral particle containing the recombinant targeting moiety.
  • the genome of the wild type virus be modified not only to accommodate the recombinant nucleic acid to be incorporated but further to attenuate the virulence of the modified virus.
  • modifications include but are not limited to the deletion of the viral genes encoding one or more DNA or RNA polymerases .
  • viruses which can be used in practicing the invention include retroviruses, adenoviruses and adeno-associated viruses (Berkner, K.L. (1988) BioTechni ues 6 . :616-629) .
  • the Examples describe viral vehicles that demonstrate preferential targeting to cultured mammalian cells expressing the erythropoietin receptor.
  • the viral vehicle targets those cells within the organism expressing the erythropoietin receptor.
  • a specific utility for such a vehicle is the treatment of hemoglobinopathies such as sickle cell anemia and ⁇ - thalassemia. These diseases involve a genetic defect wherein either an abnormal globin chain is made or little if any /3-globin chain is produced.
  • the resulting virus vehicle is capable of preferentially recognizing not only red blood cells but also those precursors of red blood cells derived from hematopoietic stem cells that have committed to erythroid differentiation as evidenced by the display of the erythropoietin receptor.
  • the virus transfects such erythroid progenitor cells, the /3-globin gene is integrated into the genome of the progenitor cells.
  • a normal /3-globin gene becomes integrated into the genome and is capable of modulating the disease by producing either normal amounts of /3-globin or the wild type /3-globin protein.
  • the viral vehicles of the invention can also be used to target the delivery of therapeutic agents to diseased cells such as cancer cells.
  • diseased cells such as cancer cells.
  • an appropriate targeting moiety can be used to target a viral vehicle to bind to such preferentially expressed markers.
  • the genome of the viral vehicle is recombined with a nucleic acid expression unit capable of expressing for example toxic polypeptides such as ricin, diphtheria toxin and the like. Upon recognition, binding and transfection into the cancer cell, the expression unit produces the toxic polypeptide to preferentially kill the cancer cell.
  • the expression unit comprises nucleic acid encoding the toxic polypeptide and one or more expression regulation sequences that are operably linked to the nucleic acid such that the nucleic acid is expressed in the transfected cancer cell so as to produce the toxic polypeptide.
  • expression regulation sequences are preferably those which demonstrate tissue specific specificity to the cell type from which the cancer cell differentiated, more preferably an expression regulation sequence expressed exclusively by the cancer cell and most preferably the expression regulation sequence controlling the expression of the preferentially expressed surface marker.
  • the preferred virus of choice is selected from the retrovirus family. Retroviruses are preferred because they require an actively dividing cell to efficiently integrate into the genome of its host. If non- cancerous cells also express the surface marker preferentially displayed on a cancer cell, the viral vehicle of the invention is also capable of recognizing, binding and transfecting such cells. This background level depends upon the amount of the surface marker found on such normal cells and the environment within which the marker is displayed. Further, to the extent that the viral vehicle contains a normal viral coat protein, e.g., envelope protein, present in combination with the recombinant targeting moiety, the viral vehicle may also have the ability to non-specifically transfect cells independent of the presence of the surface marker utilized for recognition by the targeting moiety. When a retrovirus is used to practice the invention to treat cancer cells, however, such background infections in non-cancer cells are less likely to cause damage to normal cells that are not rapidly dividing since viral integration and expression of the toxic gene is less likely to occur.
  • retrovirus is used to practice the invention to treat cancer cells, however, such background
  • oncogenes The overexpression of oncogenes is often associated with the onset and development of cancer.
  • the oncogenes expressed encode receptors which are located on the surface of the cancer cell .
  • the proto- oncogene HER2 encodes a transmembrane tyrosine kinase whose overexpression has been correlated with several human malignancies, including breast, ovarian, gastric and endometrial cancers as well as non-small cell lung adeno carcinoma. See Holmes, et al. (1992) Science 256.
  • the protein heregulin-o has a single affinity binding site for tumor cell lines expressing the HER2 oncogene.
  • the heregulin- ⁇ . protein is therefore a candidate for use in treating the above identified cancers according to the teachings disclosed herein.
  • T-cell mediated autoimmune disease is characterized by a sub- population of T-cells containing a T-cell antigen receptor
  • mice which is capable of recognizing and interacting with a self-antigen to elicit the autoimmune response.
  • Experimental autoimmune encephalomyelitis is a myelin basic protein induced demyelinating disease in mice. Recently, it has been shown that this disease is based, in part, upon the presence of a sub-population of T-cells containing well-defined variable regions containing specific segment subsets from the T-cell antigen receptor repertoire. It has also been recently reported that mice treated with monoclonal antibodies specific to epitopes contained within the /3-chain of the TCAR of the sub- population of T-cells responsible for the autoimmune disease is capable of preventing onset of the disease when the animal is challenged with myelin basic protein.
  • the vehicle of the invention can be used as an alternate approach to treating or preventing such autoimmune diseases.
  • a monoclonal antibody specific for the TCAR responsible for the autoimmune disease is used to form the vehicle of the invention.
  • the substance contained within the virus is preferably a toxic gene capable of being expressed when transfected into those T- cells containing the autoimmune inducing TCAR.
  • the substance contained therein can be a nucleic acid containing an expressible gene encoding a toxic polypeptide or a therapeutic agent such as a chemotherapeutic agent capable of killing the cell, e.g., the ricin or diphtheria toxin proteins.
  • liposome vehicles can be used to practice the invention.
  • Liposomes are well known to those skilled in the art and generally comprise membranous vesicles containing lipid bilayers which are capable of encapsulating various drugs or other chemicals. See, e.g., U.S. Pat. Nos. 4,053,585; 4,397,846; 4,411,894; 4,427,649, and Papahadjopolous, et al . (1967) Biochem. Biophvs. Acta. 135 :639; Bangham, J. et al . (1965) J. Mol. Biol. 12:238, 252; Bapzri and Korn (1973) Biochem. Biophys . Acta. 298 :1015; and Miyamato, et al . (1971) "Preparation and Characteristics of Lipid Vesicles", J. Membrane Biol. 4:252-269.
  • a drug or other chemical When a drug or other chemical is incorporated into a liposome, that substance is generally included in the reaction mixture used to synthesize the liposome. Accordingly, in practicing the invention to form liposome vehicles, the substance to be contained in the compartment of the liposome vehicle, e.g., nucleic acid, drug or therapeutic agent, is included during liposome synthesis. Further, the targeting moiety of the invention is also included during the formation of the liposome.
  • the targeting moiety When using a liposome, the targeting moiety preferably contains a anchoring region and a transmembrane region, e.g., from immunoglobulin or other membrane bound protein, so as to associate with the lipid bilayer of the liposome. It, of course, also contains the domain capable of interacting with the first member of the binding pair contained on the sub-population of mammalian cells.
  • a preferred targeting moiety comprises a monoclonal antibody (preferably IgM) specific for a cell surface antigen or an antibody that has been engineered through cloning and modification to contain an anchoring and transmembrane region.
  • the thus formed liposome contains targeting moiety wherein the domain capable of interacting with the first binding member is displayed on the inner and outer surface of the liposome membrane.
  • This example describes the construction of hybrid erythropoietin + viral envelope (EPO-env) genes in eukaryotic expression vectors.
  • EPO-env erythropoietin + viral envelope
  • LTR 5' -MoMLV-long terminal repeat sequence
  • gag and pol structural genes which are normally spliced out of the env message (Weiss, R., N. Teich, H. Varmus, J. Coffin, eds. (1984) "RNA Tumor Viruses: Molecular Biology of Tumor Viruses", 2d edition, Cold Springs Harbor Laboratory, Cold Springs Harbor, NY) , were deleted, thus leaving only a small sequence in between the splicing signals remaining to be spliced.
  • Portions of the envelope were then selected for removal and replaced with the EPO coding sequence.
  • gp70 In the center of the outer protein subunit (gp70) of the envelope lies a proline-rich region which is a likely candidate domain for cell receptor recognition (Koch, W. et al . (1983) J. Virol. 4 . 5:1-9) .
  • Other sites include two regions which flank a region of homology in the amino-terminal portion of the molecule (Mark, G.E. et al . (1984) J. Virol. 49:530-539) , and sites at which point mutations give rise to a paralytogenic mutant of MoMLV (Szurek, P.F. et al . (1988) J. Virol. 6_2 .
  • EPO-env hybrid was also constructed to insert the EPO sequence in a more central location, directly overlapping the proline-rich region. Since no convenient restriction sites exist in this region, unique sites were created at positions 6250 and 6750 by means of PCR-mediated mutagenesis. These new restriction sites were used to delete the intervening env sequence and insert the EPO sequence.
  • the EPO-env constructs were transfected into the cell line PA317 (Mann, R. et al . (1983) Cell 3_3:153-159; and
  • the PA317 cell line is a derivative of NIH3T3 cells into which MoMLV genes have been stably integrated; the PA317 cells possess the gag and pol genes as well as the amphotropic env gene, but the psi packaging signal sequence is deleted. Thus, these cells produce viral proteins without assembling them into wild type
  • EPO-env plasmids were co-transfected into the PA317 cell line, along with a methotrexate-resistant dihydrofolate reductase (DHFR) gene as a selectable marker (Simonsen, C.S. et al . (1988) Nucleic Acids Res. 16:2235- 2246) , using the calcium phosphate precipitation method (Wigler, M. et al. (1979) Cell 16:77) .
  • DHFR methotrexate-resistant dihydrofolate reductase
  • the cells were selected for stable integration of the env sequences in medium containing methotrexate.
  • Cells which had stably integrated the sequence into their genomes were methotrexate-resistant and therefore survived in this medium, growing as isolated colonies when the plating density was low enough. Stable clones were picked in this manner and grown in separate wells.
  • polyclonal anti-EPO-antiserum and fluorescein-labeled secondary antibodies were used to detect EPO expression on the cell surface of hybrid EPO-env-containing cell lines by flow cytometry ( Figure 3) .
  • Example 3 Packaging of retroviral vectors This Example discloses the use of the cell lines of Example 2 to package replication-defective retroviral vectors containing the neomycin-resistance (neo R ) gene and the /3-galactosidase (/3-gal) gene.
  • neo R neomycin-resistance
  • /3-gal /3-galactosidase
  • Stable transfectants producing high levels of recombinant envelope proteins were transfected, by means of the calcium phosphate precipitation method, with replication-defective retroviral vectors which contain the psi-packaging signal, but whose gag, pol , and env genes have been deleted and replaced with genes encoding neomycin resistance (neo R ) and /3-galactosidase (/3-gal) .
  • neo R neomycin resistance
  • /3-galactosidase /3-gal
  • the target cells consisted of four types: (1) wild type HeLa cells, which are non-murine and do not express the EPO receptor (D'Andrea, A. et al. (1989) Cell 57:277- 285) , (2) HeLa cells which have been stably transfected with the EPO receptor, (3) wild type NIH3T3 cells, which are murine fibroblasts and do not express the EPO receptor, and (4) NIH3T3 cells which have been stably transfected with the EPO receptor.
  • HeLa and NIH3T3 cells were co-transfected with the EPO receptor cDNA cloned into an appropriate eukaryotic expression vector containing a methotrexate-resistant DHFR gene (Simonsen, C.S. et al . (1988) Nucleic Acids Res. 16 . :2235-2246) . After selection with methotrexate, the surviving colonies were isolated and expression of the EPO receptor was determined by a radioligand ( 125 I-EPO) binding assay (D'Andrea, A. et al . (1989) Cell 57:277-285) .
  • a radioligand 125 I-EPO binding assay
  • the sub-clone showing the highest levels of EPO receptor expression was selected and further grown in medium containing increasing concentrations of methotrexate, in order to further amplify the expression of EPO receptor.
  • Receptor levels in these cells was calculated to be on the order of about 1000 receptors per cell.
  • the Neo R //3-gal vector alone, (unpackaged) was transfected into both cell types by calcium phosphate precipitation, to confirm that the neomycin-resistance gene, whose expression is directed by the MoMLV LTR, is expressed efficiently in these cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Methods and compositions for preferentially targeting the delivery of a substance to a sub-population of mammalian cells. The vehicle of the invention includes a targeting moiety capable of associating with or forming an envelope defining a compartment that contains the substance to be delivered to the sub-population of cells. The targeting moiety also contains a domain capable of interacting with a member of a binding pair located on the surface of the sub-population of cells.

Description

METHODS AND COMPOSITIONS FOR TARGETING SPECIFIC TISSUE
This invention was made with Government support under Grant No. AM-16666, awarded by the National Institute of Health. The Government has certain rights in this invention.
FIELD OF THE INVENTION
The invention is directed to methods and compositions for preferentially targeting the delivery of a substance, such as a nucleic acid, to specific tissue.
BACKGROUND OF THE INVENTION
In the field of gene therapy, viral vectors and liposomes have been proposed to introduce genes into cells (Williams, D.A. (1988) Hematoloαv/Oncolo v Clinics of North America 2 : 211-281; and Mannino, R.J. et al . (1988) BioTechniques 6_:682-690) . Although such approaches may in some instances result in a localized administration of the vector or liposome, e.g., a viral vector administered via inhalation for localized delivery to lung tissue, a major drawback to such approaches is that there is no tissue- specific tropism. Thus, the DNA contained in the viral vector or liposome can be delivered non-specifically into many different types of cells.
Many genetic diseases are manifested in one tissue type and inserting genes non-specifically into many different cell types is not only unnecessary, but may be harmful under certain circumstances (Selden, R.F. et al . (1987) New Enσl. J. Med. 317:1067-1076) .
In addition, it is believed that most cancers originate from one cell type. At present, chemotherapy is the most widely-used approach to control cancer. Such chemotherapy, however, is not tissue specific in terms of delivery of the chemotherapeutic agent. Rather, the adverse effects imparted upon the rapidly dividing cancer cells are also imposed upon normal cells.
Although one recent publication reported the use of a protein covalently coupled to DNA to target liver cells, this approach resulted in low efficiency in DNA uptake compared to the higher efficiency attainable with viral vectors (Wu, G.Y. et al . (1988) J. Biol . Chem 263:14621-
14624) .
Given the state of the art, it is apparent that a need exists for methods and compositions for targeting the delivery of various substances to specific cell types.
Accordingly, it is an object of the invention herein to provide vehicles for targeting the delivery of a substance to specific cell types. More particularly, it is an object of the invention to provide methods and compositions for targeting the delivery of a substance such as a nucleic acid or a therapeutic agent to a sub-population of mammalian cells contained within a living organism.
SUMMARY OF THE INVENTION
In accordance with the foregoing objects, the invention includes a vehicle for preferentially targeting the delivery of a substance to a sub-population of mammalian cells. The cell sub-population is characterized by the presence of a sub-population-specific first member of a binding pair on the surface of the cells. The vehicle comprises an envelope comprising a recombinant targeting moiety defining a compartment and a substance contained in the compartment. The recombinant targeting moiety comprises first and second domains. The first domain is capable of forming or associating with the envelope of the vehicle whereas the second domain is capable interacting with the first binding member on the surface of the sub- population of cells. The invention also includes methods for preferentially targeting the delivery of a substance to the above sub- population of mammalian cells comprising contacting a population of mammalian cells containing the sub-population with the above vehicle.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 depicts the construction of a hybrid erythropoietin-viral envelope gene.
FIG. 2 depicts the Western blot analysis of packaging cell sub-clones including the detection of the erythropoietin sequence.
FIG. 3 depicts the flow cytometric analysis of packaging cell lines based upon a detection of cell surface EPO epitopes by polyclonal anti-EPO antibodies.
FIG. 4 depicts the survivability of HeLa cells (wild- type or expressing the erythropoietin receptor) which have been exposed to neomycin or the retroviral vector encoding a neomycin resistant gene containing the EPO-env protein followed by a treatment with neomycin.
FIG. 5 depicts a similar experiment with NIH3T3 cells.
DETAILED DESCRIPTION OF THE INVENTION
The invention is based upon a discovery that a virus containing a hybrid viral envelope protein containing an amino acid sequence corresponding to a portion of the sequence of erythropoietin is capable of preferentially infecting cells displaying the erythropoietin receptor on their surface. As used herein, a "vehicle" of the invention is defined as any composition comprising an envelope defining a compartment and a substance contained therein that is capable of preferentially targeting the delivery of the substance to a specific sub-population of mammalian cells. The sub-population of mammalian cells is characterized by the presence of a first member of a binding pair on the surface of the sub-population. The vehicle is further defined by the envelope which comprises a "recombinant targeting moiety" capable of forming or associating with the envelope and which imparts cell specificity to the vehicle. In this regard, the targeting moiety contains at least two domains . The first domain is capable of forming or associating with the envelope of the vehicle whereas the second domain is capable of interacting with the first member of the binding pair on the surface of the sub- population of mammalian cells.
In one embodiment of the invention the vehicle comprises a "viral vehicle". In an alternate embodiment the vehicle comprises a "liposome vehicle". The viral vehicles of the invention are generally formed from naturally occurring viruses and in particular those viruses capable of infecting eukaryotic cells, such as mammalian cells. As is well known, viruses contain a genome comprising either RNA or DNA which encode a variety of genes necessary for viral transfection and reproduction. Included within the viral genome are nucleic acid sequences encoding various enzymes, e.g., DNA or RNA polymerases and the like and structural proteins which surround the viral genome referred to as "viral coat proteins".
Some viral coat proteins make up that part of the virus particle known as the capsid. In addition, some viruses further contain a lipid bilayer surrounding the capsid which often contains viral envelope proteins. Depending upon the virus used and its envelope structure, i.e., capsid proteins only or capsid proteins in combination with membrane and envelope protein, the capsid protein or envelope protein is used to form the targeting moiety for the viral vehicle of the invention.
Since the targeting moiety contains a domain which is capable of forming or associating with the envelope of the virus vehicle, all or part of the viral coat protein is used to construct the recombinant target moiety. When only a portion of the coat protein is used, that portion of the coat protein which is necessary and sufficient for envelope formation is used. For viral envelope proteins, such necessary and essential features include the anchoring region and transmembrane region utilized by the envelope protein to display the envelope protein on an infected cell. When a virus containing an envelope protein is used, it is preferred that the targeting moiety contain such anchor and transmembrane regions .
The second domain of the target moiety is capable of interacting with the first member of a binding pair which is on the surface of a sub-population of mammalian cells. As used herein, a "binding pair" includes receptor-ligand complexes, antigen-antibody complexes, enzyme-substrate complexes and the like. Thus, a sub-population of cells can be defined by the presence of one of the binding pairs on the surface of the cells of the population. For example, those cells containing an erythropoietin receptor define a cellular sub-population that can be targeted by utilizing erythropoietin (ligand) in the targeting moiety of the invention as the second domain capable of interacting with the erythropoietin receptor. Alternatively, the receptor can be used in the targeting moiety and the ligand displayed on the surface of the cells of the sub-population.
Similarly, a sub-population of cells can be defined by the presence of an antigen or antibody on the surface of the cells contained within that population. For example, a surface marker contained on the surface of a sub- population of cells can be used to generate monoclonal antibodies by methods well known to those' skilled in the art. Monoclonal antibodies (especially those containing anchor and transmembrane regions or engineered through cloning and modification of cDNA to contain such sequences) can be used either as the targeting moiety alone (e.g., in a liposome vehicle) or in combination with a protein capable of associating with a viral surface. In an example of the latter case, the targeting moiety essentially comprises a chimeric antibody containing an anchoring and transmembrane region from a viral envelope protein coupled to at least the variable region of a heavy chain Ig molecule which is also associated with the light chain from the antibody. Alternatively, the vehicle of the invention can target a sub-population of lymphoid cells displaying a membrane bound form of an immunoglobulin. In such cases, the antigen to the membrane bound antibody is used to form the second domain of the targeting moiety.
In general, the recombinant targeting moiety used to form the vehicle of the invention contains all or part of the second member of the binding pair. In some instances, the interaction between binding pairs is based upon an interaction involving a continuous epitope. In such cases, the minimal component of the second member of the binding pair that can be used in forming a targeting moiety consists of that epitope. In many instances, however, the interaction involves a discontinuous epitope. For example, in the case of proteins, two or more regions within the primary amino acid sequence of the protein are brought into close physical proximity in the tertiary structure of the protein to form the binding epitope. When only a portion of such a protein is used to form the targeting moiety, that portion of the primary amino acid sequence which encompasses such binding regions are preferably included in the targeting moiety so as to provide the strongest possible interaction with the other member of the binding pair located on the sub-population of mammalian cells.
The vehicle of the invention preferentially targets the delivery of substance to a sub-population of mammalian cells. Such preferential targeting is defined by comparing delivery of the substance to the sub-population of mammalian cells containing the first member of a binding pair as compared to a different population of a mammalian cell of the same species which does not display the first member of the binding pair. The increase in delivery as measured by binding of the vehicle to the sub-population or transferral of the substance of the vehicle into the sub- population cells, is generally greater than two-fold. However, as indicated in the examples, an increase in efficiency in infection by the viral vehicle disclosed therein ranged from 10-fold to about 30- to 40-fold as compared to wild-type cells not containing the receptor used in that experiment . In an example herein, the recombinant targeting moiety comprises a carboxy terminal portion of the envelope protein of Moloney murine leukemia virus (MoMLV) . The second domain comprises an amino terminal portion of erythropoietin. When the plasmid encoding this construct is expressed in a packaging cell line also capable of expressing the full length MoMLV envelope protein under conditions which provide for the formation of virus particles, a viral vehicle of the invention is formed. In this particular case, the recombinant targeting moiety is associated with the envelope (corresponding to the membrane and MoMLV envelope protein) defining a compartment that contains the remainder of the virus particle. As thus formed, the substance contained within the viral compartment can comprise protein surrounding the viral genome or the genome itself. In the former case, preformed proteins capable of being packaged with viral capsid proteins can comprise the substance contained in the compartment. In most embodiments, however, the substance of interest contained within such a viral vehicle is a recombinant DNA sequence introduced into the genome of the virus. Viral vehicles are preferred when the substance to be delivered to a sub-population of cells is a nucleic acid. Thus, when used to treat a genetic disease, the skilled artisan identifies the defective gene and the cell type that expresses the normal wild type gene. Then, a surface marker is identified on the cell type normally expressing the wild type gene. The viral vehicle of the invention is then designed to contain a recombinant targeting moiety capable of forming or associating with the envelope of a selected virus such that the thus modified virus is capable of recognizing and binding the selected surface marker. In conjunction with the selection of the virus to be used in practicing the invention, the size of the recombinant nucleic acid to be incorporated into the viral genome is determined to facilitate the choice of virus to be used. The genome of the virus must be such that it can either accommodate the selected recombinant nucleic acid or be modified to delete nonessential sequences such that the recombinant nucleic acid can be incorporated into the viral genome and still be packaged to form an intact viral particle containing the recombinant targeting moiety. In this regard, it is preferred that the genome of the wild type virus be modified not only to accommodate the recombinant nucleic acid to be incorporated but further to attenuate the virulence of the modified virus. Such modifications include but are not limited to the deletion of the viral genes encoding one or more DNA or RNA polymerases . Examples of viruses which can be used in practicing the invention include retroviruses, adenoviruses and adeno-associated viruses (Berkner, K.L. (1988) BioTechni ues 6.:616-629) .
The Examples describe viral vehicles that demonstrate preferential targeting to cultured mammalian cells expressing the erythropoietin receptor. Thus, when used in vivo, the viral vehicle targets those cells within the organism expressing the erythropoietin receptor. A specific utility for such a vehicle is the treatment of hemoglobinopathies such as sickle cell anemia and β- thalassemia. These diseases involve a genetic defect wherein either an abnormal globin chain is made or little if any /3-globin chain is produced. If a genomic clone encoding the /3-globin gene is inserted into the genome of the virus vehicle in the Examples, the resulting virus vehicle is capable of preferentially recognizing not only red blood cells but also those precursors of red blood cells derived from hematopoietic stem cells that have committed to erythroid differentiation as evidenced by the display of the erythropoietin receptor. When the virus transfects such erythroid progenitor cells, the /3-globin gene is integrated into the genome of the progenitor cells. As a consequence, a normal /3-globin gene becomes integrated into the genome and is capable of modulating the disease by producing either normal amounts of /3-globin or the wild type /3-globin protein. The viral vehicles of the invention can also be used to target the delivery of therapeutic agents to diseased cells such as cancer cells. For example, to the extent a surface marker is preferentially expressed on a cancer cell (i.e., solely on the surface of the cancer cell or at a level higher than that found on non-cancerous cell-types) , an appropriate targeting moiety can be used to target a viral vehicle to bind to such preferentially expressed markers. The genome of the viral vehicle is recombined with a nucleic acid expression unit capable of expressing for example toxic polypeptides such as ricin, diphtheria toxin and the like. Upon recognition, binding and transfection into the cancer cell, the expression unit produces the toxic polypeptide to preferentially kill the cancer cell. In this regard, the expression unit comprises nucleic acid encoding the toxic polypeptide and one or more expression regulation sequences that are operably linked to the nucleic acid such that the nucleic acid is expressed in the transfected cancer cell so as to produce the toxic polypeptide. Such expression regulation sequences are preferably those which demonstrate tissue specific specificity to the cell type from which the cancer cell differentiated, more preferably an expression regulation sequence expressed exclusively by the cancer cell and most preferably the expression regulation sequence controlling the expression of the preferentially expressed surface marker.
In such embodiments, the preferred virus of choice is selected from the retrovirus family. Retroviruses are preferred because they require an actively dividing cell to efficiently integrate into the genome of its host. If non- cancerous cells also express the surface marker preferentially displayed on a cancer cell, the viral vehicle of the invention is also capable of recognizing, binding and transfecting such cells. This background level depends upon the amount of the surface marker found on such normal cells and the environment within which the marker is displayed. Further, to the extent that the viral vehicle contains a normal viral coat protein, e.g., envelope protein, present in combination with the recombinant targeting moiety, the viral vehicle may also have the ability to non-specifically transfect cells independent of the presence of the surface marker utilized for recognition by the targeting moiety. When a retrovirus is used to practice the invention to treat cancer cells, however, such background infections in non-cancer cells are less likely to cause damage to normal cells that are not rapidly dividing since viral integration and expression of the toxic gene is less likely to occur.
The overexpression of oncogenes is often associated with the onset and development of cancer. In many instances, the oncogenes expressed encode receptors which are located on the surface of the cancer cell . For example, it has been recently disclosed that the proto- oncogene HER2 encodes a transmembrane tyrosine kinase whose overexpression has been correlated with several human malignancies, including breast, ovarian, gastric and endometrial cancers as well as non-small cell lung adeno carcinoma. See Holmes, et al. (1992) Science 256. As further disclosed, the protein heregulin-o; has a single affinity binding site for tumor cell lines expressing the HER2 oncogene. The heregulin-α. protein is therefore a candidate for use in treating the above identified cancers according to the teachings disclosed herein.
In addition to cancer cells, the invention can be used for treating autoimmune disease. For example, T-cell mediated autoimmune disease is characterized by a sub- population of T-cells containing a T-cell antigen receptor
(TCAR) which is capable of recognizing and interacting with a self-antigen to elicit the autoimmune response. Experimental autoimmune encephalomyelitis (EAE) is a myelin basic protein induced demyelinating disease in mice. Recently, it has been shown that this disease is based, in part, upon the presence of a sub-population of T-cells containing well-defined variable regions containing specific segment subsets from the T-cell antigen receptor repertoire. It has also been recently reported that mice treated with monoclonal antibodies specific to epitopes contained within the /3-chain of the TCAR of the sub- population of T-cells responsible for the autoimmune disease is capable of preventing onset of the disease when the animal is challenged with myelin basic protein.
Since other T-cell-mediated autoimmune diseases are believed to form the basis of various autoimmune diseases, especially in humans, the vehicle of the invention can be used as an alternate approach to treating or preventing such autoimmune diseases. In such cases, a monoclonal antibody specific for the TCAR responsible for the autoimmune disease is used to form the vehicle of the invention. When a viral vehicle is used, the substance contained within the virus is preferably a toxic gene capable of being expressed when transfected into those T- cells containing the autoimmune inducing TCAR. Alternatively, when a liposome is used, the substance contained therein can be a nucleic acid containing an expressible gene encoding a toxic polypeptide or a therapeutic agent such as a chemotherapeutic agent capable of killing the cell, e.g., the ricin or diphtheria toxin proteins.
In addition to viral vehicles, liposome vehicles can be used to practice the invention. Liposomes are well known to those skilled in the art and generally comprise membranous vesicles containing lipid bilayers which are capable of encapsulating various drugs or other chemicals. See, e.g., U.S. Pat. Nos. 4,053,585; 4,397,846; 4,411,894; 4,427,649, and Papahadjopolous, et al . (1967) Biochem. Biophvs. Acta. 135 :639; Bangham, J. et al . (1965) J. Mol. Biol. 12:238, 252; Bapzri and Korn (1973) Biochem. Biophys . Acta. 298 :1015; and Miyamato, et al . (1971) "Preparation and Characteristics of Lipid Vesicles", J. Membrane Biol. 4:252-269.
When a drug or other chemical is incorporated into a liposome, that substance is generally included in the reaction mixture used to synthesize the liposome. Accordingly, in practicing the invention to form liposome vehicles, the substance to be contained in the compartment of the liposome vehicle, e.g., nucleic acid, drug or therapeutic agent, is included during liposome synthesis. Further, the targeting moiety of the invention is also included during the formation of the liposome.
When using a liposome, the targeting moiety preferably contains a anchoring region and a transmembrane region, e.g., from immunoglobulin or other membrane bound protein, so as to associate with the lipid bilayer of the liposome. It, of course, also contains the domain capable of interacting with the first member of the binding pair contained on the sub-population of mammalian cells. A preferred targeting moiety comprises a monoclonal antibody (preferably IgM) specific for a cell surface antigen or an antibody that has been engineered through cloning and modification to contain an anchoring and transmembrane region.
Since the targeting moiety is not produced within the liposome but rather is incorporated into the liposome membrane during liposome formation, the thus formed liposome contains targeting moiety wherein the domain capable of interacting with the first binding member is displayed on the inner and outer surface of the liposome membrane.
The following is presented by way of examples and is not to be construed as limitation of the scope of the claims appended hereto.
Example 1 Construction of hybrid EPO-env genes
This example describes the construction of hybrid erythropoietin + viral envelope (EPO-env) genes in eukaryotic expression vectors.
The entire wild type moloney murine leukemia virus (MoMLV) envelope gene { env gene; from position 5760 to position 7820 of the retroviral genome; Shinnick, T.M. et al. (1981) Nature 293 :543-548) was cloned into a pBR322- based plasmid vector. Transcription of the env gene is driven by the 5' -MoMLV-long terminal repeat sequence (LTR) . The psi (packaging signal) sequence was deleted, but the vector retained the 5' and 3' splicing signals for the env mRNA. The intervening gag and pol structural genes, which are normally spliced out of the env message (Weiss, R., N. Teich, H. Varmus, J. Coffin, eds. (1984) "RNA Tumor Viruses: Molecular Biology of Tumor Viruses", 2d edition, Cold Springs Harbor Laboratory, Cold Springs Harbor, NY) , were deleted, thus leaving only a small sequence in between the splicing signals remaining to be spliced.
Portions of the envelope were then selected for removal and replaced with the EPO coding sequence. In the center of the outer protein subunit (gp70) of the envelope lies a proline-rich region which is a likely candidate domain for cell receptor recognition (Koch, W. et al . (1983) J. Virol. 4.5:1-9) . Other sites include two regions which flank a region of homology in the amino-terminal portion of the molecule (Mark, G.E. et al . (1984) J. Virol. 49:530-539) , and sites at which point mutations give rise to a paralytogenic mutant of MoMLV (Szurek, P.F. et al . (1988) J. Virol. 6_2.:357-360) . These regions are target sites for replacement with EPO. At the same time, portions of the gp70 sequence which encode the env signal peptide at the amino terminus, as well as the cysteine residues in the carboxyl-terminal region which participate in sulfhydryl bonding with the inner envelope subunit (pl5) , were left intact (Shinnick, T.M. et al . (1981) Nature 293:543-548) . Unique restriction sites exist at position 5923 (BstEII) and position 6537 (BamHI) . Deletion of the envelope sequence between these two sites preserves the env signal sequence and allows the EPO sequence (approximately 500 base pairs in length) to be inserted at the amino-terminal end of gp70. A second EPO-env hybrid was also constructed to insert the EPO sequence in a more central location, directly overlapping the proline-rich region. Since no convenient restriction sites exist in this region, unique sites were created at positions 6250 and 6750 by means of PCR-mediated mutagenesis. These new restriction sites were used to delete the intervening env sequence and insert the EPO sequence. The EPO cDNA sequence coding for the mature 166-amino acid peptide hormone without the 27 amino acid signal peptide (Jacobs, K. et al. (1985) Nature 313:806-810; and Lin, F.K. et al. (1985) Proc. Natl . Acad. Sci. USA 82:7580- 7584) , was used to replace the MoMLV env sequences (Shinnick, T.M. et al. (1981) Nature 293:543-548) which had been deleted in the amino-terminal end and the central region of the envelope protein. PCR-mediated mutagenesis (Innis, M.A., Gelfand, D.H., Sninsky, J.J., White, T.J., eds. (1990) "PCR Protocols: A Guide to Methods and Applications", Academic Press, San Diego, CA) was used to create compatible ends on the EPO sequence, so that it could be inserted via the appropriate restriction sites while maintaining the proper reading frame (Figure 1) .
Example 2 Construction of packaging cell lines containing the EPO-env genes
The EPO-env constructs were transfected into the cell line PA317 (Mann, R. et al . (1983) Cell 3_3:153-159; and
Cone, R.D. et al. (1984) Proc. Natl. Acad. Sci. USA .81:6349-6353) . The PA317 cell line is a derivative of NIH3T3 cells into which MoMLV genes have been stably integrated; the PA317 cells possess the gag and pol genes as well as the amphotropic env gene, but the psi packaging signal sequence is deleted. Thus, these cells produce viral proteins without assembling them into wild type
(endogenous) virus, and can be used to package exogenous viral vectors which do contain the psi sequence into virions with an amphotropic (i.e., capable of infecting both murine and non-murine cells) . The EPO-env plasmids were co-transfected into the PA317 cell line, along with a methotrexate-resistant dihydrofolate reductase (DHFR) gene as a selectable marker (Simonsen, C.S. et al . (1988) Nucleic Acids Res. 16:2235- 2246) , using the calcium phosphate precipitation method (Wigler, M. et al. (1979) Cell 16:77) . After transfection, the cells were selected for stable integration of the env sequences in medium containing methotrexate. Cells which had stably integrated the sequence into their genomes were methotrexate-resistant and therefore survived in this medium, growing as isolated colonies when the plating density was low enough. Stable clones were picked in this manner and grown in separate wells.
After stably transfected sub-clones were isolated, Western blot and flow cytometric analyses were performed to confirm that the recombinant envelope proteins were being expressed and that they were reaching the surface of the packaging cell. Monoclonal anti-EPO antibodies and biotinylated secondary antibodies were used to detect expression in Western blots using a chemiluminescence-based technique (Linscott, W.D. (1990) Linscott's Directory of Immunological and Biological Reagents, 6th ed. , Mill Valley, CA) , and the EPO-env hybrid protein was detected as an intact 70 kiloDalton band in some sub-clones, but seemed to have been deleted or rearranged in others (Figure 2) . Using the parental cell line PA317 as a negative control, polyclonal anti-EPO-antiserum and fluorescein-labeled secondary antibodies were used to detect EPO expression on the cell surface of hybrid EPO-env-containing cell lines by flow cytometry (Figure 3) .
Example 3 Packaging of retroviral vectors This Example discloses the use of the cell lines of Example 2 to package replication-defective retroviral vectors containing the neomycin-resistance (neoR) gene and the /3-galactosidase (/3-gal) gene.
Stable transfectants producing high levels of recombinant envelope proteins were transfected, by means of the calcium phosphate precipitation method, with replication-defective retroviral vectors which contain the psi-packaging signal, but whose gag, pol , and env genes have been deleted and replaced with genes encoding neomycin resistance (neoR) and /3-galactosidase (/3-gal) . These vectors were also transfected into the parental wild type amphotropic packaging cell line PA317 as a control. The cell culture supernatant containing these transiently expressed viruses was harvested, filtered to remove cellular debris, and used to infect target cells with or without the EPO receptor.
Example 4
Tissue specificity and infection efficiency of the packaged virus
The target cells consisted of four types: (1) wild type HeLa cells, which are non-murine and do not express the EPO receptor (D'Andrea, A. et al. (1989) Cell 57:277- 285) , (2) HeLa cells which have been stably transfected with the EPO receptor, (3) wild type NIH3T3 cells, which are murine fibroblasts and do not express the EPO receptor, and (4) NIH3T3 cells which have been stably transfected with the EPO receptor.
HeLa and NIH3T3 cells were co-transfected with the EPO receptor cDNA cloned into an appropriate eukaryotic expression vector containing a methotrexate-resistant DHFR gene (Simonsen, C.S. et al . (1988) Nucleic Acids Res. 16.:2235-2246) . After selection with methotrexate, the surviving colonies were isolated and expression of the EPO receptor was determined by a radioligand (125I-EPO) binding assay (D'Andrea, A. et al . (1989) Cell 57:277-285) . The sub-clone showing the highest levels of EPO receptor expression was selected and further grown in medium containing increasing concentrations of methotrexate, in order to further amplify the expression of EPO receptor. Receptor levels in these cells was calculated to be on the order of about 1000 receptors per cell. As an additional positive control prior to the infection experiments, the NeoR//3-gal vector alone, (unpackaged) was transfected into both cell types by calcium phosphate precipitation, to confirm that the neomycin-resistance gene, whose expression is directed by the MoMLV LTR, is expressed efficiently in these cells.
All cells exposed to virus were subjected to selection with neomycin, and the surviving colonies were examined and counted after Giemsa staining. There proved to be an increased efficiency of infection when viruses expressing the recombinant EPO-env protein were contacted with cells bearing the EPO receptor, as compared to cells without the receptor. This increased efficiency was about 10-fold in the case of HeLa cells with EPO receptor (Figure 4) , and 30- to 40-fold in the case of NIH3T3 cells with EPO receptor (Figure 5) , compared to their respective wild type cells without the receptor. Having described the preferred embodiments, it will be apparent to those skilled in the art that various modifications can be made to the embodiments disclosed herein and that such modifications are intended to be within the scope of the invention.

Claims

WHAT IS CLAIMED IS:
1. A vehicle for preferentially targeting the delivery of a substance to a sub-population of mammalian cells characterized by the presence of a first member of a binding pair on the surface of said sub-population, said vehicle comprising an envelope comprising a recombinant targeting moiety defining a compartment and a substance contained in said compartment, wherein said targeting moiety comprises first and second domains not naturally associated with each other and wherein said first domain forms or associates with the envelope defining said compartment and said second domain comprises a second member of said binding pair or portion thereof which targets said vehicle to said sub-population of mammalian cells.
2. The vehicle of Claim 1 wherein said vehicle is capable of transferring said substance into said cell.
3. The vehicle of Claim 1 wherein said substance is a therapeutic agent.
4. the vehicle of Claim 3 wherein said therapeutic agent is a nucleic acid.
5. The vehicle of Claim 2 wherein said substance comprises a recombinant viral genome.
6. The vehicle of Claim 1 wherein said envelope comprises a membrane.
7. The vehicle of Claim 1 wherein said envelope comprises a viral coat protein.
8. The vehicle of Claim 7 wherein said viral coat protein comprises a viral envelope protein.
9. The vehicle of Claim 7 wherein said first domain of said targeting moiety comprises a portion of a viral coat protein.
10. The vehicle of Claim 9 wherein said viral coat protein comprises a viral envelope protein.
11. A method for preferentially targeting the delivery of a substance to a sub-population of mammalian cells characterized by the presence of a specific surface receptor for a ligand, said method comprising contacting a population of mammalian cells containing said sub- population with any one of the vehicles of Claims 1 through 10 and 12 wherein said receptor and said ligand comprise said first and said second members of said binding pair.
12. The vehicle of Claim 1 wherein said binding pair comprises erythropoietin and erythropoietin receptor.
EP93914334A 1992-06-08 1993-06-03 Methods and compositions for targeting specific tissue. Withdrawn EP0650370A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90609292A 1992-06-08 1992-06-08
US906092 1992-06-08
PCT/US1993/005260 WO1993025234A1 (en) 1992-06-08 1993-06-03 Methods and compositions for targeting specific tissue

Publications (2)

Publication Number Publication Date
EP0650370A1 true EP0650370A1 (en) 1995-05-03
EP0650370A4 EP0650370A4 (en) 1995-11-22

Family

ID=25421920

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93914334A Withdrawn EP0650370A4 (en) 1992-06-08 1993-06-03 Methods and compositions for targeting specific tissue.

Country Status (3)

Country Link
EP (1) EP0650370A4 (en)
JP (1) JPH07507689A (en)
WO (1) WO1993025234A1 (en)

Families Citing this family (265)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011524A1 (en) 1992-11-09 1994-05-26 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Targetable vector particles
GB9402857D0 (en) 1994-02-15 1994-04-06 Isis Innovation Targeting gene therapy
US6150137A (en) 1994-05-27 2000-11-21 Ariad Pharmaceuticals, Inc. Immunosuppressant target proteins
GB9412844D0 (en) * 1994-06-27 1994-08-17 Medical Res Council Improvements in or relating to therapeutic methods
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
AU727531B2 (en) * 1995-07-25 2000-12-14 Crucell Holland B.V. Methods and means for targeted gene delivery
GB9519776D0 (en) 1995-09-28 1995-11-29 Casimir Colin Materials and methods relating to the transfer of nucleic acid into stem cells
EP0880596A1 (en) * 1995-12-28 1998-12-02 Chiron Corporation Receptor specific chimeric viral surface polypeptides for viral and particle incorporation and internalization in target cells
DE19605279A1 (en) * 1996-02-13 1997-08-14 Hoechst Ag Target cell-specific vectors for the introduction of genes into cells, drugs containing such vectors and their use
CA2266656A1 (en) 1996-09-17 1998-03-26 Chiron Corporation Compositions and methods for treating intracellular diseases
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
DE69839243T2 (en) 1997-04-10 2009-04-30 University Of Southern California, Los Angeles MODIFIED PROTEINS ADHERING TO EXTRACELLULAR MATRIX COMPONENTS
US6004798A (en) * 1997-05-14 1999-12-21 University Of Southern California Retroviral envelopes having modified hypervariable polyproline regions
US6162641A (en) * 1997-06-06 2000-12-19 The Regents Of The University Of Michigan Neuregulin response element and uses therefor
DE69838584T2 (en) 1997-08-04 2008-06-26 Cell Genesys, Inc., Foster City ENHANCERS OF HUMAN GLANDULAR CALLIQUE, VECTORS CONTAINING HIM, AND METHODS FOR ITS USE
JP2002516061A (en) 1997-10-14 2002-06-04 ダーウィン モレキュラー コーポレイション Mutants of thymidine kinase and fusion proteins having thymidine kinase activity and guanylate kinase activity
BR9813930A (en) 1997-11-06 2006-12-19 Chiron Spa neisserial antigen
WO1999036544A2 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
US7078483B2 (en) 1998-04-29 2006-07-18 University Of Southern California Retroviral vectors including modified envelope escort proteins
JP5102414B2 (en) 1998-05-01 2012-12-19 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド Meningococcal antigens and compositions
WO2001031019A2 (en) 1999-10-29 2001-05-03 Chiron Spa Neisserial antigenic peptides
EP0972841A1 (en) * 1998-05-20 2000-01-19 Introgene B.V. Display of viral proteins as ligands for cell-surface receptor
EP0959135A1 (en) * 1998-05-20 1999-11-24 Introgene B.V. Display of viral proteins and targeted delivery to cellular receptor
EP0960942A3 (en) * 1998-05-20 2000-01-12 Introgene B.V. Targeted delivery through a cationic amino acid transporter
EP0959136A1 (en) * 1998-05-20 1999-11-24 Introgene B.V. Targeted delivery through a cationic amino acid transporter
EP1121437B1 (en) 1998-10-15 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Metastatic breast and colon cancer regulated genes
NZ512122A (en) 1998-11-27 2003-12-19 Darwin Discovery Ltd Compositions and methods for increasing bone mineralization
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
EP1141331B1 (en) 1998-12-16 2008-09-17 Novartis Vaccines and Diagnostics, Inc. HUMAN CYCLIN-DEPENDENT KINASE (hPNQALRE)
US7063850B1 (en) 1998-12-22 2006-06-20 University Of Tennessee Research Foundation Protective antigen of group A Streptococci
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
CA2360347C (en) 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6911429B2 (en) 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
CN100392082C (en) 1999-04-30 2008-06-04 启龙股份公司 Conserved neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
US7396905B1 (en) 1999-05-21 2008-07-08 Mckeon Frank Calcipressins: endogenous inhibitors of calcineurin, uses and reagents related thereto
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
ES2335386T3 (en) 1999-11-18 2010-03-26 Novartis Vaccines And Diagnostics, Inc. GEN FGF-21 HUMAN AND GENE EXPRESSION PRODUCTS.
US6951839B1 (en) 1999-11-30 2005-10-04 Curis, Inc. Methods and compositions for regulating lymphocyte activity
US8168178B2 (en) 1999-11-30 2012-05-01 Curis, Inc. Methods and compositions for regulating lymphocyte activity
CN1416352B (en) 2000-01-17 2011-05-25 启龙股份公司 Outer membrane vesicle (OMV) vaccine comprising N. Meningitidis serogroup B outer membrane
EP1854476A3 (en) 2000-02-09 2008-05-07 Bas Medical, Inc. Use of relaxin to treat diseases related to vasoconstriction
WO2001066595A2 (en) 2000-03-08 2001-09-13 Chiron Corporation Human fgf-23 gene and gene expression products
EP1950297A2 (en) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
WO2003057926A1 (en) 2002-01-08 2003-07-17 Chiron Corporation Gene products differentially expressed in cancerous breast cells and their methods of use
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
ES2398391T3 (en) 2000-06-15 2013-03-15 Novartis Vaccines And Diagnostics, Inc. Polynucleotides related to colon cancer
EP1328543B1 (en) 2000-10-27 2009-08-12 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups a & b
EP2336368A1 (en) 2000-12-07 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Endogenous retroviruses up-regulated in prostate cancer
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
CA2433877C (en) 2001-01-17 2014-11-18 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
WO2002079447A2 (en) 2001-03-30 2002-10-10 Avigenics, Inc. Avian lysozyme promoter
US7541512B2 (en) 2001-03-30 2009-06-02 Synageva Biopharma Corp. Avians containing a lysozyme promoter transgene
US7176300B2 (en) 2001-03-30 2007-02-13 Avigenics, Inc. Avian lysozyme promoter
AU2002305151A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
WO2002081642A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
JP4353701B2 (en) 2001-05-08 2009-10-28 ダーウィン モレキュラー コーポレイション Method for regulating immune function in primates using FOXP3 protein
EP2280074A3 (en) 2001-07-05 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
US7550650B2 (en) 2001-09-18 2009-06-23 Synageva Biopharma Corp. Production of a transgenic avian by cytoplasmic injection
AU2002365223A1 (en) 2001-10-26 2003-09-02 Id Biomedical Corporation Of Washington Multivalent streptococcal vaccine compositions and methods for use
ES2345329T3 (en) 2001-11-09 2010-09-21 Georgetown University NEW ISOFORM OF THE VASCULAR ENDOTELIAL CELLULAR GROWTH INHIBITOR (VEGI).
US6875588B2 (en) 2001-11-30 2005-04-05 Avigenics, Inc. Ovomucoid promoter and methods of use
US7335761B2 (en) 2001-11-30 2008-02-26 Avigenics, Inc. Avian gene expression controlling regions
US7294507B2 (en) 2001-11-30 2007-11-13 Avigenics, Inc. Ovomucoid promoters and methods of use
ES2386386T3 (en) 2001-12-12 2012-08-20 Novartis Vaccines And Diagnostics S.R.L. Immunization against Chlamydia trachomatis
US7135562B2 (en) 2002-03-14 2006-11-14 University Of Cincinnati Avian iFABP gene expression controlling region
MXPA04008890A (en) 2002-03-15 2005-10-18 Wyeth Corp Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity.
EP2093233A1 (en) 2002-03-21 2009-08-26 Sagres Discovery, Inc. Novel compositions and methods in cancer
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US8518694B2 (en) 2002-06-13 2013-08-27 Novartis Vaccines And Diagnostics, Inc. Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
CA2421269A1 (en) 2002-08-09 2004-02-09 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
EP1575517B1 (en) 2002-12-24 2012-04-11 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
US20070149449A1 (en) 2003-02-14 2007-06-28 Morris David W Therapeutic targets in cancer
EP1594441B1 (en) 2003-02-19 2010-12-15 Rinat Neuroscience Corp. Method for treating pain by administering a nerve growth factor antagonist and an nsaid and composition containing the same
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
EP1619951B1 (en) 2003-04-21 2011-06-22 Epeius Biotechnologies Corporation Methods and compositions for treating disorders
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
US20060025337A1 (en) 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
WO2005020928A2 (en) 2003-08-29 2005-03-10 The Regents Of The University Of California Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
WO2005062955A2 (en) 2003-12-23 2005-07-14 Rinat Neuroscience Corp. Agonist anti-trkc antibodies and methods using same
JP4792390B2 (en) 2004-03-29 2011-10-12 株式会社ガルファーマ Novel galectin-9 variant protein and use thereof
AU2005243247B2 (en) 2004-04-07 2012-03-01 Regents Of The University Of Minnesota Methods for treating bone cancer pain by administering a nerve growth factor antagonist
US7875275B2 (en) 2004-06-16 2011-01-25 The General Hospital Corporation Use of Bridge-1 and activators and inhibitors thereof in the treatment of insulin deficiency and diabetes
PT2495252T (en) 2004-07-09 2018-06-22 Henry M Jackson Found Advancement Military Medicine Inc Soluble forms of hendra and nipah virus g glycoprotein
CA2573720A1 (en) 2004-07-14 2006-02-23 University Of Utah Research Foundation Netrin-related compositions and uses
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
GEP20115195B (en) 2004-07-30 2011-04-11 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and use thereof
ES2385045T3 (en) 2005-02-18 2012-07-17 Novartis Vaccines And Diagnostics, Inc. Urotogenic Escherichia coli immunogens
WO2006110599A2 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. Cacna1e in cancer diagnosis, detection and treatment
JP2008535853A (en) 2005-04-07 2008-09-04 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド Cancer-related genes
AU2006272713A1 (en) 2005-07-22 2007-02-01 Y's Therapeutics Co, Ltd. Anti-CD26 antibodies and methods of use thereof
SI1912675T1 (en) 2005-07-25 2014-07-31 Emergent Product Development Seattle, Llc B-cell reduction using cd37-specific and cd20-specific binding molecules
ES2433251T5 (en) 2005-11-14 2020-03-13 Teva Pharmaceuticals Int Gmbh Antagonistic antibodies directed against a peptide related to the calcitonin gene and procedures using them
EP1988920A1 (en) 2006-02-02 2008-11-12 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkb antagonist
WO2007098281A2 (en) 2006-02-27 2007-08-30 Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
CN103709252B (en) 2006-06-07 2016-12-07 生物联合公司 Identify antibody and the using method thereof of the sugary epi-position of CD-43 and CEA expressed on cancerous cell
US20110206692A1 (en) 2006-06-09 2011-08-25 Novartis Ag Conformers of bacterial adhesins
CA2654317A1 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
TR201807756T4 (en) 2006-09-26 2018-06-21 Infectious Disease Res Inst Vaccine composition containing synthetic adjuvant.
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
WO2008092041A2 (en) 2007-01-24 2008-07-31 Carnegie Mellon University Optical biosensors
EP2139447A2 (en) 2007-03-20 2010-01-06 Harold Brem Gm-csf cosmeceutical compositions and methods of use thereof
US20100261640A1 (en) 2007-04-10 2010-10-14 Branco Luis M Soluble and membrane anchored forms of lassa virus subunit proteins
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
US9526737B2 (en) 2007-12-03 2016-12-27 The Regents Of The University Of California Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling
JP5737944B2 (en) 2007-12-17 2015-06-17 ファイザー・リミテッドPfizer Limited Treatment of interstitial cystitis
DK2245063T3 (en) 2007-12-18 2015-12-07 Bioalliance Cv Antibodies that recognize carbohydrate AN EPITOPE ON CD-43 AND CEA expressed CANCER CELLS AND PRACTICES BY WHICH THEY USED
AU2009234389B2 (en) 2008-04-10 2014-08-21 Cell Signaling Technology, Inc. Compositions and methods for detecting EGFR mutations in cancer
PT2132228E (en) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US7928189B2 (en) 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
TWI516501B (en) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Pcsk9 antagonists
CN102224254A (en) 2008-09-23 2011-10-19 哈佛大学校长及研究员协会 Sirt4 and uses thereof
US9181315B2 (en) 2009-01-08 2015-11-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
JP2012515532A (en) 2009-01-20 2012-07-12 ラモット アット テル アビブ ユニバーシティ, リミテッド MIR-21 promoter driven target cancer treatment
US9719069B2 (en) 2009-01-27 2017-08-01 University Of Utah Research Foundation Methods and compositions relating to viral latency
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
US8568732B2 (en) 2009-03-06 2013-10-29 Novartis Ag Chlamydia antigens
EP3293257B1 (en) 2009-03-20 2021-08-11 Mesoblast, Inc. Production of reprogrammed pluripotent cells
US20100297127A1 (en) 2009-04-08 2010-11-25 Ghilardi Nico P Use of il-27 antagonists to treat lupus
SG175092A1 (en) 2009-04-14 2011-11-28 Novartis Ag Compositions for immunising against staphylococcus aerus
CA3065736A1 (en) 2009-04-27 2010-11-04 Ottawa Hospital Research Institute Compositions and methods for modulating stem cells and uses thereof
EP2437753B1 (en) 2009-06-05 2016-08-31 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
SG178035A1 (en) 2009-07-16 2012-03-29 Novartis Ag Detoxified escherichia coli immunogens
WO2011038063A1 (en) 2009-09-28 2011-03-31 The Trustees Of The University Of Pennsylvania Method of diagnosing and treating interstitial cystitis
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011091272A1 (en) 2010-01-21 2011-07-28 Dana-Farber Cancer Institute, Inc. Context specific genetic screen platform to aid in gene discovery and target validation
AR080291A1 (en) 2010-02-24 2012-03-28 Rinat Neuroscience Corp ANTI-BODIES ANTAGONISTS ANTI RECEIVER OF IL-7 AND PROCEDURES
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
AU2011225716A1 (en) 2010-03-11 2012-09-27 Pfizer Inc. Antibodies with pH dependent antigen binding
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
EP2598126A2 (en) 2010-07-30 2013-06-05 Saint Louis University Methods of treating pain
US9539427B2 (en) 2010-11-08 2017-01-10 The Johns Hopkins University Methods for improving heart function
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
WO2012075243A2 (en) 2010-12-01 2012-06-07 The University Of North Carolina At Chapel Hill Methods and compositions for targeting sites of neovascular growth
EP2659271A4 (en) 2010-12-27 2015-04-08 Univ Brown Therapeutic and diagnostic methods involving biglycan and utrophin
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US20130071375A1 (en) 2011-08-22 2013-03-21 Saint Louis University Compositions and methods for treating inflammation
WO2013028527A1 (en) 2011-08-23 2013-02-28 Indiana University Research And Technology Corporation Compositions and methods for treating cancer
US10093705B2 (en) 2011-09-13 2018-10-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using FNDC5
WO2013055911A1 (en) 2011-10-14 2013-04-18 Dana-Farber Cancer Institute, Inc. Znf365/zfp365 biomarker predictive of anti-cancer response
CA2854720C (en) 2011-11-11 2018-12-18 Rinat Neuroscience Corp. Antibodies specific for trop-2 and their uses
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
US9249224B2 (en) 2011-12-22 2016-02-02 Rinat Neuroscience Corp. Human growth hormone receptor antagonist antibodies and methods of use thereof
CN104363892A (en) 2012-02-07 2015-02-18 传染性疾病研究院 Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
MX359257B (en) 2012-05-04 2018-09-19 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens.
EP2847206A4 (en) 2012-05-07 2016-01-20 Univ California Oxysterol analogue oxy133 induces osteogenesis and hedgehog signaling and inhibits adipogenesis
RS57420B1 (en) 2012-05-16 2018-09-28 Immune Design Corp Vaccines for hsv-2
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
MX2015005874A (en) 2012-11-09 2015-09-10 Pfizer Platelet-derived growth factor b specific antibodies and compositions and uses thereof.
WO2014153205A1 (en) 2013-03-14 2014-09-25 Epeius Biotechnologies Corporation Thymidine kinase diagnostic assay for gene therapy applications
KR20150132473A (en) 2013-03-15 2015-11-25 다이액스 코포레이션 Anti-plasma kallikrein antibodies
CA2909221A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
CA2911205A1 (en) 2013-05-02 2014-11-06 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents
JP2016520058A (en) 2013-05-07 2016-07-11 ライナット ニューロサイエンス コーポレイション Anti-glucagon receptor antibodies and methods of use thereof
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EP3008043A2 (en) 2013-06-14 2016-04-20 University Of Utah Research Foundation Triazol-1-ol analogs anti-retroviral latency drugs
EP3044314B1 (en) 2013-07-12 2019-04-10 SeNa Research, Inc. Methods and compositions for interference with dna polymerase and dna synthesis
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
MX371455B (en) 2013-08-02 2020-01-28 Pfizer Anti-cxcr4 antibodies and antibody-drug conjugates.
SG10201810298VA (en) 2013-11-13 2018-12-28 Pfizer Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
MX2016012188A (en) 2014-03-21 2017-04-27 Teva Pharmaceuticals Int Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same.
AU2015249374A1 (en) 2014-04-24 2016-12-01 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
EP3139955B1 (en) 2014-04-30 2024-03-20 President and Fellows of Harvard College Fusion proteins for treating cancer and related methods
KR102246800B1 (en) 2014-05-13 2021-04-30 바이오아트라, 인코퍼레이티드 Conditionally active biological proteins
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US11111288B2 (en) 2014-08-28 2021-09-07 Bioatla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
CA2959141A1 (en) 2014-08-28 2016-03-03 Bioatla, Llc Conditionally active chimeric antigen receptors for modified t-cells
AU2015311911B2 (en) 2014-09-03 2019-01-24 Bioatla, Llc Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
US20180133252A9 (en) 2014-09-09 2018-05-17 Unum Therapeutics Inc. Chimeric receptors and uses thereof in immune therapy
AU2015328411C1 (en) 2014-10-06 2022-03-03 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
AU2015328163B2 (en) 2014-10-09 2020-10-15 Dana-Farber Cancer Institute, Inc. Multiple-variable IL-2 dose regimen for treating immune disorders
TWI595006B (en) 2014-12-09 2017-08-11 禮納特神經系統科學公司 Anti-pd-1 antibodies and methods of use thereof
WO2016144673A1 (en) 2015-03-06 2016-09-15 Dana-Farber Cancer Institute, Inc. Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers
US20180042998A1 (en) 2015-03-10 2018-02-15 University Of Massachusetts Targeting gdf6 and bmp signaling for anti-melanoma therapy
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
PE20221262A1 (en) 2015-04-13 2022-08-16 Pfizer THERAPEUTIC ANTIBODIES AND THEIR USES
US10877045B2 (en) 2015-07-21 2020-12-29 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
EP4011916A1 (en) 2015-07-21 2022-06-15 Takeda Pharmaceutical Company Limited A monoclonal antibody inhibitor of factor xiia
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
KR20230074843A (en) 2015-08-19 2023-05-31 화이자 인코포레이티드 Tissue factor pathway inhibitor antibodies and uses thereof
EP3350220B1 (en) 2015-09-15 2021-05-19 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
EP3352760A4 (en) 2015-09-21 2019-03-06 Aptevo Research and Development LLC Cd3 binding polypeptides
JP7017506B2 (en) 2015-10-16 2022-02-08 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク Compositions and Methods for Inhibition of Strain-Specific Antigens
EP3362074B1 (en) 2015-10-16 2023-08-09 President and Fellows of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
WO2017070561A1 (en) 2015-10-23 2017-04-27 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
WO2017075037A1 (en) 2015-10-27 2017-05-04 Scholar Rock, Inc. Primed growth factors and uses thereof
WO2017075329A2 (en) 2015-10-29 2017-05-04 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
CN106699889A (en) 2015-11-18 2017-05-24 礼进生物医药科技(上海)有限公司 PD-1 resisting antibody and treatment application thereof
IL290457B1 (en) 2015-12-30 2024-10-01 Kodiak Sciences Inc Antibodies and conjugates thereof
DK3405490T3 (en) 2016-01-21 2022-01-10 Pfizer MONO- AND BISPECIFIC ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III AND CD3 AND USES THEREOF
US20210309965A1 (en) 2016-03-21 2021-10-07 Dana-Farber Cancer Institute, Inc. T-cell exhaustion state-specific gene expression regulators and uses thereof
US11254742B2 (en) 2016-05-13 2022-02-22 Bioatla, Inc. Anti-Ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
IL314130A (en) 2016-05-16 2024-09-01 Access To Advanced Health Inst Formulation containing tlr agonist and methods of use
BR112018074352B1 (en) 2016-06-01 2021-11-30 Infectious Disease Research Institute NANOALUME PARTICLES CONTAINING A SIZING AGENT
JP7099967B2 (en) 2016-07-01 2022-07-12 リサーチ ディベロップメント ファウンデーション Elimination of Proliferative Cells from Stem Cell-Derived Grafts
CA3034643A1 (en) 2016-09-20 2018-03-29 Ellen Weisberg Compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators
WO2018080573A1 (en) 2016-10-28 2018-05-03 Massachusetts Institute Of Technology Crispr/cas global regulator screening platform
US20190345501A1 (en) 2017-02-07 2019-11-14 Massachusetts Institute Of Technology Methods and compositions for rna-guided genetic circuits
US11198735B2 (en) 2017-03-03 2021-12-14 Rinat Neuroscience Corp. Anti-GITR antibodies and methods of use thereof
WO2018167621A1 (en) 2017-03-16 2018-09-20 Pfizer Inc. Tyrosine prototrophy
WO2018191548A2 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
JP7234142B2 (en) 2017-06-02 2023-03-07 ファイザー・インク Antibodies specific for FLT3 and uses thereof
US11820822B2 (en) 2017-06-06 2023-11-21 Dana-Farber Cancer Institute, Inc. Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathways
US20180357361A1 (en) 2017-06-13 2018-12-13 Feliks Frenkel Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy
WO2019016784A1 (en) 2017-07-21 2019-01-24 Universidade De Coimbra Anti-nucleolin antibody
CN111093715A (en) 2017-09-18 2020-05-01 儿童医院医疗中心 Strong insulator and use thereof in gene delivery
AU2018344859A1 (en) 2017-10-04 2020-04-30 Hesperix SA Articles and methods directed to personalized therapy of cancer
CN112020518A (en) 2018-02-01 2020-12-01 辉瑞公司 Chimeric antigen receptor targeting CD70
KR20200115596A (en) 2018-02-01 2020-10-07 화이자 인코포레이티드 Antibodies specific for CD70 and uses thereof
SG11202007518RA (en) 2018-02-28 2020-09-29 Pfizer Il-15 variants and uses thereof
MX2020009152A (en) 2018-03-02 2020-11-09 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof.
KR102584675B1 (en) 2018-05-23 2023-10-05 화이자 인코포레이티드 Antibodies specific for GUCY2c and their uses
SG11202010580TA (en) 2018-05-23 2020-12-30 Pfizer Antibodies specific for cd3 and uses thereof
KR20210030950A (en) 2018-07-03 2021-03-18 소티오, 엘엘씨 Chimeric receptors in combination with trans metabolic molecules that enhance glucose uptake and their therapeutic uses
US12077785B2 (en) 2018-08-14 2024-09-03 Sotio Biotech Inc. Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating Krebs cycle and therapeutic uses thereof
JP2022520138A (en) 2018-08-28 2022-03-29 ブイオーアール バイオファーマ インコーポレーテッド Genetically engineered hematopoietic stem cells and their use
CN114144190A (en) 2019-01-23 2022-03-04 纽约大学 Antibodies specific for the delta 1 chain of T cell receptors
ES2967696T3 (en) 2019-04-08 2024-05-03 Giuseppe Scalabrino Epidermal growth factor (EGF) and variants thereof for treating or preventing inflammatory demyelinating disorders
EP3962529A4 (en) 2019-04-30 2023-11-01 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
EP3994696A2 (en) 2019-07-03 2022-05-11 BostonGene Corporation Systems and methods for sample preparation, sample sequencing, and sequencing data bias correction and quality control
AU2020363372A1 (en) 2019-10-07 2022-05-19 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
EP4041773A1 (en) 2019-10-11 2022-08-17 Beth Israel Deaconess Medical Center, Inc. Anti-tn antibodies and uses thereof
EP4093426A1 (en) 2020-01-24 2022-11-30 University of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
WO2021224850A1 (en) 2020-05-06 2021-11-11 Crispr Therapeutics Ag Mask peptides and masked anti-ptk7 antibodies comprising such
KR20230022246A (en) 2020-07-17 2023-02-14 화이자 인코포레이티드 Therapeutic Antibodies and Uses Thereof
EP4189093A1 (en) 2020-07-30 2023-06-07 Pfizer Inc. Cells having gene duplications and uses thereof
EP4229222A2 (en) 2020-10-19 2023-08-23 Dana-Farber Cancer Institute, Inc. Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
WO2022104104A2 (en) 2020-11-13 2022-05-19 Dana-Farber Cancer Institute, Inc. Personalized fusion cell vaccines
US20220180972A1 (en) 2020-12-04 2022-06-09 Bostongene Corporation Hierarchical machine learning techniques for identifying molecular categories from expression data
WO2022159793A2 (en) 2021-01-25 2022-07-28 Dana-Farber Cancer Institute, Inc. Methods and compositions for identifying neuroendocrine prostate cancer
US20220372580A1 (en) 2021-04-29 2022-11-24 Bostongene Corporation Machine learning techniques for estimating tumor cell expression in complex tumor tissue
US20240280561A1 (en) 2021-06-08 2024-08-22 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
EP4380969A1 (en) 2021-08-02 2024-06-12 Pfizer Inc. Improved expression vectors and uses thereof
KR20240069799A (en) 2021-09-27 2024-05-20 소티오 바이오테크 인크. Chimeric receptor polypeptides in combination with trans-metabolic molecules that redirect glucose metabolites out of the glycolytic pathway and their therapeutic uses
WO2023091909A1 (en) 2021-11-16 2023-05-25 Sotio Biotech Inc. Treatment of myxoid/round cell liposarcoma patients
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
WO2023147177A1 (en) 2022-01-31 2023-08-03 Bostongene Corporation Machine learning techniques for cytometry
WO2023148598A1 (en) 2022-02-02 2023-08-10 Pfizer Inc. Cysteine prototrophy
AU2023221961A1 (en) 2022-02-16 2024-09-26 Dana-Farber Cancer Institute, Inc. Methods for decreasing pathologic alpha-synuclein using agents that modulate fndc5 or biologically active fragments thereof
US20240029884A1 (en) 2022-07-15 2024-01-25 Bostongene Corporation Techniques for detecting homologous recombination deficiency (hrd)
WO2024040207A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof
WO2024040208A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000103A1 (en) * 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Chimeric envelope proteins for viral targeting
WO1993022433A2 (en) * 1992-04-28 1993-11-11 Frank Andreas Harald Meyer Medicament for the gene-therapeutic treatment of human beings, animals and plants, especially to block virus multiplication and carcinogenes and process for producing the medicament

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000103A1 (en) * 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Chimeric envelope proteins for viral targeting
WO1993022433A2 (en) * 1992-04-28 1993-11-11 Frank Andreas Harald Meyer Medicament for the gene-therapeutic treatment of human beings, animals and plants, especially to block virus multiplication and carcinogenes and process for producing the medicament

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 111, no. 13, 25 September 1989 Columbus, Ohio, US; abstract no. 110248, EGLITIS, MARTIN A. ET AL 'Retroviral-mediated gene transfer into hemopoietic cells' & ADV. EXP. MED. BIOL. (1988), 241(MOL. BIOL. HEMOPOIESIS), 19-27 CODEN: AEMBAP;ISSN: 0065-2598, 1988 *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US AN=93:312729, & J. CELL BIOCHEM. SUPPL. , vol. 0, 1993 page 237 KASAHARA N. ET AL. 'TARGETED GENE DELIVERY BY RETROVIRUSES WITH PEPTIDE HORMONE SEQUENCES INCORPORATED INTO THE ENVELOPE.' *
NATURE (LONDON) (1990), 343(6260), 762-4 CODEN: NATUAS;ISSN: 0028-0836, 1990 LI, JING PO ET AL 'Activation of cell growth by binding of Friend spleen focus-forming virus gp55 glycoprotein to the erythropoietin receptor' *
NATURE, vol. 320, 20 March 1986 LONDON GB, pages 275-277, RANDY A. HOCK ET AL. 'RETROVIRUS-MEDIATED TRANSFER AND EXPRESSION OF DRUG RESISTANCE GENES IN HUMAN HAEMATOPOIETIC PROGENITOR CELLS.' *
PROC. NATL. ACAD. SCI. U. S. A. (1990), 87(11), 4139-43 CODEN: PNASA6;ISSN: 0027-8424, 1990 YOSHIMURA, AKIHIKO ET AL 'Friend spleen focus-forming virus glycoprotein gp55 interacts with the erythropoietin receptor in the endoplasmic reticulum and affects receptor metabolism' *
See also references of WO9325234A1 *

Also Published As

Publication number Publication date
EP0650370A4 (en) 1995-11-22
WO1993025234A1 (en) 1993-12-23
JPH07507689A (en) 1995-08-31

Similar Documents

Publication Publication Date Title
WO1993025234A1 (en) Methods and compositions for targeting specific tissue
EP0670905B1 (en) Recombinant viruses displaying a nonviral polypeptide on their external surface
US7033834B2 (en) Methods and means for targeted gene delivery
US7820157B2 (en) Transgene delivering retrovirus targeting collagen exposed at site of tissue injury
Fielding et al. Inverse targeting of retroviral vectors: selective gene transfer in a mixed population of hematopoietic and nonhematopoietic cells
JP5031921B2 (en) Hyperproliferative combination therapy
EP0769968B1 (en) Retroviral vectors produced by producer cell lines resistant to lysis by human serum
JP2009112314A (en) Method and composition for treating disorder
JP2002522090A (en) Cell type-specific gene transfer using a retroviral vector containing an antibody envelope fusion protein and a wild type envelope protein
Gleiter et al. Cell-type specific targeting and gene expression using a variant of polyoma VP1 virus-like particles
EP1204761B1 (en) Targeted artificial gene delivery
Lee et al. Gene delivery using a receptor‐mediated gene transfer system targeted to hepatocellular carcinoma cells
AU693904B2 (en) Improvements in or relating to delivery of nucleic acids
WO1997019180A2 (en) Vector consisting of a transcriptional regulatory dna sequence linked to a dna sequence encoding beta-lactamase for enzyme prodrug therapy
JP4509780B2 (en) Method for preparing virus particles with modified cell binding activity and use thereof
JPH10511551A (en) Virus vector complex with an adapter with a predetermined valency
CN112876566A (en) Construction and application of CD3 specific lentivirus
US20020164583A1 (en) Targeting viral vectors to specific cells
Benedict et al. Development of Retroviral Vectors that Target Hematopoietic Stem Cells
WO1997038119A1 (en) Reagent and method for targeting retrovirus
Reddy Folate-targeted gene delivery to cancers
Benedict The murine leukemia virus envelope protein: engineering for vector targeting and analysis of interactions with viral core proteins
WO1998049335A1 (en) Construct and expression of a retrovirus chimerical envelope by vectors, and pharmaceutical compositions containing same
AU2005202079A1 (en) Targeted artificial gene delivery

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19941124

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19951006

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RHK1 Main classification (correction)

Ipc: A61K 39/12

17Q First examination report despatched

Effective date: 19980605

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19991125